Cell dynamics in disease and therapy

我们的计划支持和鼓励临床科学家探索细胞动力学的潜力，以识别和评估治疗人类疾病的生物标记物和靶点。这一领域包括基因组动力学和可移动的细胞间隔，但也包括心肌细胞和神经元，这两种细胞都是具有特殊要求的可兴奋细胞。该计划的参与者在他们的实习期间专门花了18个月的时间来开发一个有竞争力的研究计划。他们利用尖端技术来研究与疾病相关的细胞变化和操纵它们进行治疗的选择。我们的计划建立在已建立的、外部资助的、面向临床科学家的小规模计划的基础上，并显著扩展了与知名研究财团的互动，例如，新成立的卓越集群2067“多尺度生物成像：从分子机器到可兴奋细胞的网络”，由德国癌症援助机构新资助的综合癌症中心，以及哥廷根大学医学中心(UMG)的四个合作研究中心和三个研究单位。事实证明，该计划的主要特点特别有帮助。这些措施包括：外部审查员透明地挑选候选人；候选人必须与临床和科学主管达成协议；受保护的研究时间分几个月进行，包括选择外部研究轮换；与位于哥廷根的马克斯·普朗克研究所合作；严格的质量管理；以及指导和指导的最佳做法模式。尽管大流行，我们项目的参与者还是去了外部研究机构，例如哈佛医学院和当地的马克斯·普朗克研究所。一些首批科学出版物正在记录他们的成功，尽管大多数成员参与的时间不到一年。外部审查和咨询委员会继续通过视频会议开展活动，我们主要资格课程的讲师也是如此。在新的资助期内，我们将尽一切努力进一步鼓励我们计划的成员与导师和同事进行个人互动，无论他们在哪里，都能充分利用科学讨论和合作的机会。这将包括由与会者组织的一次科学大会，这是基于我们过去设立的类似大会取得的令人印象深刻的成功。我们将使这个项目成为UMG的永久机构，允许未来几代临床医生科学家从事雄心勃勃的转化性研究。这将使他们能够对我们关于基于细胞的疾病机制的知识以及对当地和全球卫生作出强有力的贡献。

Our program supports and encourages Clinician Scientists who explore the potential of cell dynamics to identify and evaluate biomarkers and targets to treat human diseases. This field includes genome dynamics and mobile cellular compartments, but also cardiomyocytes and neurons, both excitable cell species with specific requirements. The participants of the program dedicate >18 months during their residency exclusively to develop a competitive research program. They take advantage of cutting edge technologies to study disease-associated cellular alterations and options to manipulate them for therapy. Our program builds upon and significantly expands established, externally funded, small-scale programs for Clinician Scientists, and upon the interaction with high-profile research consortia, e.g. the newly established Cluster of Excellence 2067 “Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells”, the Comprehensive Cancer Center newly funded by the German Cancer Aid, as well as four Collaborative Research Centers and three Research Units of University Medical Center Göttingen (UMG). Key features of the program have proven to be particularly helpful. Those include transparent selection of candidates by external reviewers; mandatory agreements of candidates with clinical and scientific supervisors; protected research time in blocks of several months, including the option of external research rotations; collaboration with Max Planck Institutes in Göttingen; rigorous quality management; and best-practice models of guidance and mentoring. Despite the pandemics, the participants of our program went for external research stays, e.g. at Harvard Medical School and at local Max Planck Institutes. A number of first scientific publications are documenting their success, although most members were participating for less than a year. The external review and advisory board has continued its activity through videoconferences, and so did the instructors of our key qualification courses. Within the new funding period, we will make every effort to further encourage the members of our program towards personal interactions with mentors and colleagues, wherever located, to fully exploit the opportunities for scientific discussions and collaborations. This will include a scientific congress organized by the participants, based on the impressive success of a similar congress that we set up in the past. We will make this program a permanent institution at UMG, allowing future generations of Clinician Scientists to pursue ambitious translational research. This will enable them to make strong contributions to our knowledge on cell-based disease mechanisms as well as to local and global health.